Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 943 results for "novartis"

CSL completes $275m Novartis vaccines acquisition

Novartis flu vaccine business bought by CSL

CSL (ASX:CSL) has completed its acquisition of the Novartis global influenza vaccine business for a cash consideration of US$275 million. The closing of the transaction will enable the integration of the influenza vaccines division with CSL's ... Australian Life Scientist, 13 hours ago
CSL finalises flu vaccine purchase Finance News Network, 1 day ago

742 images for novartis

Bio Spectrum Asia, 1 week ago
Pharmafile, 1 week ago, 1 week ago, 1 week ago
Business Insider, 1 week ago
Business Insider, 1 week ago
Reuters India, 1 week ago
Digital Look, 2 weeks ago
Reuters India, 1 week ago
OncLive, 1 week ago

Potential Novartis AG (NVS) Trade Has 6.65% Downside Protection

A covered call identified by's patented algorithm on Novartis AG ("NVS) could yield about 3.25% (7.19% annualized, for comparison purposes only) in 165 days. Pair a long ...
 Individual.com1 day ago Novartis AG (NVS) Showing Support Near $101.95  Individual.com4 days ago Novartis AG (NVS) Showing Bearish Technicals With Resistance At $104.09  Individual.com1 week ago Potential Novartis AG (NVS) Trade Targets 3.53% Return  Individual.com6 days ago

CSL acquires influenza vaccines business from Novartis

CSL Limited, an Australia-based developer, manufacturer, and marketer of products to treat and prevent serious human medical conditions, has acquired the influenza vaccine business from Novartis AG, a Switzerland-based developer, manufacturer and ...
 Individual.com1 day ago Novartis : completes divestiture of influenza vaccines business to CSL Limited for USD 275 million  4 Traders1 day ago Novartis spins out assets to Mereo BioPharma  MedNous2 days ago Bexsero ▼  Irish Medical Times3 days ago
Business Insider Australia

CSL share inch towards $100

A MAJOR factor behind the surge in CSL's share price has been the $US275 million acquisition of Novartis's global
 Brisbane Courier-Mail1 day ago CSL shares inching towards $100 (AAP)  Yahoo! News Australia1 day ago CSL is the first ASX stock to hit $100 since the GFC  Business Insider Australia19 hours ago By Trevor Chappell CSL Shares: CSL shares inching towards $100  Geelong Advertiser1 day ago

Novating Novartis

Biotech investors can be better at valuing and nurturing small drugs than Big Pharma. Recognising this, Novartis is spinning three drugs-in-development into a new entity backed by UK investors. With biotech markets hot, there's room for copycat ...
 Smart Investor4 days ago Novartis spinoff is neat cure for Big Pharma ills  Reuters UK5 days ago
Global Information Inc

Research and Markets: Global Statin Market 2015-2019 with AstraZeneca, Merck, Novartis & Pfizer Dominating Business Wire

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( ) has announced the addition of the "Global Statin Market 2015-2019" report to their offering. The global statin ...
 Yahoo! Finance4 days ago Global Diabetic Retinopathy Market 2015-2019 with Bayer, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating  Individual.com5 days ago Global Statin Market 2015-2019 with AstraZeneca, Merck, Novartis & Pfizer Dominating  Individual.com4 days ago Research and Markets: Global Diabetic Retinopathy Market 2015-2019 with Bayer, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating  Reuters5 days ago
WA Today

Early wind up for CSL, Novartis vaccine deal

 Pharma In Focus1 day ago CSL closer to Novartis flu vaccine deal  NineMSN Finance4 days ago CSL completes Novartis flu vaccine deal  WA Today1 day ago

Why Novartis case will help innovation

The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's ...
 The Hindu3 days ago

Novartis's Shares Fall after 2Q15 Earnings

Novartis Stock Falls after 2Q15 Earnings Release ( Continued from Prior Part ) Shares declined ~2% after earnings Novartis (NVS) reported its earnings on July 21, 2015, at 8:00 AM EST. After the release, shares closed at $103.71, down ~2.3% ...
 Yahoo! Finance5 days ago Novartis's Adjusted Earnings per Share Declined 7% in 2Q15  Yahoo! Finance1 week ago Biogen's Experimental Alzheimer Therapy: Limited 2Q15 Success  Yahoo! News3 days ago
Bio Spectrum Asia

Novartis partners with Mereo BioPharma to enhance novel drug portfolio

Singapore: Novartis has partnered with UK based Mereo BioPharma to develop compounds including BPS-804, to improve bone density in brittle bone syndrome, an orphan disease; BCT-197 for acute exacerbations in COPD, and BGS-649 for obese men with ...
 Bio Spectrum Asia4 days ago ICON Forms Partnership with Mereo BioPharma for Clinical Development  PharmiWeb3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis
Get updated on latest news & your favorite topics right in your inbox!
More     Less